Sulthiame

DB08329

small molecule approved

Deskripsi

Struktur Molekul 2D

Berat 290.359
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food. Taking sulthiame with food, may reduce gastrointestinal upset.

Interaksi Obat

916 Data
Buprenorphine Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Hydrocodone Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Magnesium sulfate The therapeutic efficacy of Sulthiame can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Sulthiame may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Mirtazapine Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Orphenadrine Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Pramipexole Sulthiame may increase the sedative activities of Pramipexole.
Ropinirole Sulthiame may increase the sedative activities of Ropinirole.
Rotigotine Sulthiame may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Sulthiame.
Sodium oxybate Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Thalidomide Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Sulthiame can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Sulthiame can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Sulthiame resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Sulthiame may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Sulthiame.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Sulthiame.
Ethanol Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Fluvoxamine The risk or severity of adverse effects can be increased when Sulthiame is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Sulthiame is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Sulthiame is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Sulthiame is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Sulthiame is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Sulthiame is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Sulthiame is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Sulthiame is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Sulthiame is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Sulthiame is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Sulthiame is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Sulthiame is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Sulthiame is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Sulthiame is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Sulthiame is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Sulthiame is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Sulthiame is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Sulthiame.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Sulthiame.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Sulthiame.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Sulthiame.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Sulthiame.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Sulthiame.
Cocaine The risk or severity of methemoglobinemia can be increased when Sulthiame is combined with Cocaine.
Quinidine The therapeutic efficacy of Sulthiame can be decreased when used in combination with Quinidine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Sulthiame.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Sulthiame.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Sulthiame.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Sulthiame.
Dosulepin The risk or severity of CNS depression can be increased when Sulthiame is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Sulthiame is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Sulthiame.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Sulthiame.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Sulthiame.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Sulthiame.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Sulthiame.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Sulthiame.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Sulthiame.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Sulthiame.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Sulthiame.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Sulthiame.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Sulthiame.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Sulthiame.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Sulthiame.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Sulthiame.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Sulthiame.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Sulthiame.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Sulthiame.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Sulthiame.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Sulthiame.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Sulthiame.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Sulthiame.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Sulthiame.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Sulthiame.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Sulthiame.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Sulthiame.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Sulthiame.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Sulthiame.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Sulthiame.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Sulthiame.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Sulthiame.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Sulthiame.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Sulthiame.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Sulthiame.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Sulthiame.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Sulthiame.

Target Protein

Carbonic anhydrase 2 CA2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 4
International Brands
  • Conadil
  • Contravul
  • Elisal
  • Ospolot

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul